Woodline Partners’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.02M Buy
16,226
+728
+5% +$257K 0.02% 668
2026
Q2
$5.56M Buy
15,498
+12,692
+452% +$3.88M 0.02% 671
2026
Q1
$703K Sell
2,806
-7,282
-72% -$1.81M ﹤0.01% 923
2025
Q4
$2.78M Sell
10,088
-242,128
-96% -$66.2M 0.01% 732
2025
Q3
$66.2M Buy
+252,216
New +$61.3M 0.31% 67
2025
Q2
– Sell
-138,871
Closed -$31.1M – 1064
2025
Q1
$31.1M Buy
138,871
+119,417
+614% +$32.9M 0.2% 154
2024
Q4
$6.37M Buy
+19,454
New +$6.12M 0.04% 438
2024
Q2
– Sell
-166,588
Closed -$65.9M – 689
2024
Q1
$65.9M Buy
166,588
+147,018
+751% +$54.4M 0.61% 39
2023
Q4
$6.89M Buy
+19,570
New +$6.93M 0.07% 273
2023
Q2
– Sell
-81,725
Closed -$28.3M – 764
2023
Q1
$28.3M Buy
81,725
+32,453
+66% +$9.48M 0.39% 78
2022
Q4
$11.6M Buy
+49,272
New +$11.7M 0.16% 186
2021
Q1
– Sell
-33,980
Closed -$9.6M – 480
2020
Q4
$9.6M Buy
+33,980
New +$9.5M 0.26% 118

Other funds holding WST

Woodline Partners's WST Position: Q3 2026 in Review

Woodline Partners increased its West Pharmaceutical (WST) stake by 4.7% in Q3 2026, buying an estimated $257K and bringing the position to 16,226 shares worth $6.02M. The position accounts for 0.02% of the portfolio, ranked #668.

Woodline Partners first reported a position in WST in Q4 2020 and has held it in 12 quarters since. The position peaked at $66.2M in Q3 2025. 878 funds tracked by Wall St. Rank hold WST as of Q3 2026.

  • Woodline Partners held 16,226 shares of West Pharmaceutical worth $6.02M as of Q3 2026.
  • Woodline Partners bought 728 West Pharmaceutical shares in Q3 2026, an estimated $257K.
  • West Pharmaceutical made up 0.02% of Woodline Partners's portfolio in Q3 2026, its #668 holding.
  • Woodline Partners first reported a position in West Pharmaceutical in Q4 2020 and has held it in 12 quarters since.
  • Woodline Partners's West Pharmaceutical position peaked at $66.2M in Q3 2025.
  • 878 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.